Key Highlights from the Annual Report

• Fiscal Year End: December 31, 2025. The company has filed its annual report for the period ending December 31, 2025, under the Securities Exchange Act of 1934.
• Trading Information: Common Stock, par value \$0.0001 per share, trades under the symbol HUMA on The Nasdaq Stock Market LLC.
• Warrants: Redeemable warrants are exercisable for one share of Common Stock at an exercise price of \$11.50, also listed on Nasdaq.
• Public Float: As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately \$280.3 million.
• Shares Outstanding: As of March 24, 2026, there were 222,019,108 shares of common stock issued and outstanding.
• Company Status: Humacyte is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company or a shell company.
• Filing Compliance: The company confirms it has filed all required reports during the previous 12 months and has posted all Interactive Data Files as per regulations.
• No Error Corrections or Restatements: The financial statements do not reflect corrections of previous errors or restatements that would trigger compensation clawbacks.
• No Attestation of Internal Controls: The annual report does not include an auditor attestation of internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.
• Documents Incorporated by Reference: Portions of the Proxy Statement for the 2026 Annual Meeting of Shareholders are incorporated by reference.

Potentially Price-Sensitive Information and Issues for Shareholders

• Market Value and Share Count: The company’s high number of shares outstanding and a substantial public float may affect future trading liquidity and volatility, especially in the context of additional equity offerings, warrant exercises, or major institutional transactions.
• Warrant Structure: The existence of a large number of redeemable warrants could impact dilution and the company’s future financing options. Investors should monitor any conversions or redemptions that could affect the share count and market price.
• Filer Status and Reporting: As a smaller reporting company and non-accelerated filer, Humacyte is subject to lighter reporting requirements. This may limit the frequency and scope of disclosures compared to larger companies, which investors should consider when evaluating transparency and governance.
• Internal Controls: The absence of a required auditor attestation on internal controls over financial reporting could be a point of concern for investors who prioritize robust financial governance and risk management.
• No Error Restatements: The absence of financial restatements or error corrections indicates stability in financial reporting, which is generally positive for investor confidence.

Additional Details for Investors

• Regulatory Compliance: Humacyte confirms compliance with all applicable Securities Exchange Act filing requirements, including posting of interactive data files and all periodic reports.
• Legal Proceedings & Risk Factors: The table of contents indicates that detailed discussions on legal proceedings, risk factors, and management’s analysis of operations are included in the full filing. Investors should review these sections for updates on operational risks, litigation, or regulatory matters that may impact the company.
• Market for Equity Securities: The report includes a section on market data, related stockholder matters, and equity securities transactions, which may provide insights into recent capital raises, buybacks, or changes in shareholder composition.
• Shareholder Meetings: The Proxy Statement for the 2026 Annual Meeting contains important governance and executive compensation information, which is incorporated by reference into this filing.

Conclusion

The filing of Humacyte’s 2025 Annual Report contains no immediate red flags such as restatements, non-compliance, or internal control failures, but investors should note the company’s capital structure, warrant overhang, and non-accelerated filer status. Any future developments regarding warrant exercises, additional stock issuance, or changes in reporting status could be price sensitive and should be monitored closely.